Navigation Links
NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
Date:8/14/2009

EMERYVILLE, Calif., Aug. 14 /PRNewswire-FirstCall/ -- NovaBay((R)) Pharmaceuticals, Inc. (NYSE Amex: NBY), a clinical stage biopharmaceutical company developing first-in-class anti-infective products for the treatment and prevention of a wide range of infections without causing resistance, reported today its financial results and operational highlights for the second quarter of 2009 ended June 30, 2009.

License and collaboration revenue for the second quarter of 2009 increased $ 0.9 million to $2.3 million from $1.4 million for the second quarter of 2008. This revenue consisted almost exclusively of amounts earned under the license and collaboration agreements with Alcon (NYSE: ACL), and beginning with this quarter, Galderma S.A., for amortization of the upfront technology access fees, receipt of milestone payments, and other amounts that have been reimbursed for the funding of research and development activities performed during the period.

The net loss for the second quarter of 2009 was $0.3 million, or $0.01 per share, compared to a net loss of $2.4 million, or $0.11 per share, reported for the second quarter of 2008. As of June 30, 2009, the company's cash, cash equivalents and short-term investments totaled $10.7 million, a net decrease of only $1.4 million from the $12.1 million reported at December 31, 2008. This represents a 75% reduction from the $5.5 million decrease during the first six months of 2008. The decreased burn rate in 2009 was largely due to cost containment measures, delayed research, development, and clinical expenses and receipt of a milestone and higher reimbursement payments from Alcon and upfront payments fr
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
2. NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
3. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
4. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
5. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
6. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
7. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
8. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
9. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
11. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... AZ (PRWEB) February 28, 2015 Increasing its ... World Films launches its first three episodes of The GMO ... Mile Project this month, as it continues its mission to ... launch, the project's first phase, to “uncover the truth about ... of media. , The GMO Truth Podcast is an expansion ...
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... toxicology studies for its newly developed Bruton,s tyrosine ... have been completed. The results of these preclinical ... and Drug Administration. The feedback received from the ... ongoing first-in-human study. Additional preclinical work is required ...
(Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... stage vaccine and immunotherapy company, today announced that ... its application for Fast Track designation and Phase ... vaccines, in conjunction with the mutual co-development agreement ... previously obtained Fast Track designation for the DPX-Survivac. ...
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015  Pfenex ... in the development of biosimilar therapeutics, today announced that ... San Francisco Marriott Marquis on March 2 nd ... will participate on a panel discussing the current state ... World of Biosimilars . For more ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... Quantum Information and Quantum Control at the University of Toronto ... Physics World magazine. , Steinberg led an international ... two-slit interferometer experiment in which a beam of light shone ... screen behind. That famous experiment and the 1927 debates ...
... Coatings, Inc. (OTCQB: ECOC), a leader in the ... developed bio-based GRAS (generally recognized as safe) UV-curable materials ... be used to make coatings that are safe for ... with food and food packaging. Ecology has ...
... AMSTERDAM, December 15, 2011 Amsterdam Molecular Therapeutics ... therapy, announced today that the Company has a negative equity ... of this negative equity position is in line with previous ... is exploring alternatives for additional financing. AMT announced ...
Cached Biology Technology:U of Toronto experiment named top breakthrough of 2011 by Physics World 2Ecology Coatings Develops Coatings Safe for Direct Contact with Food Products 2Amsterdam Molecular Therapeutics Announces Negative Equity Position 2Amsterdam Molecular Therapeutics Announces Negative Equity Position 3
(Date:2/5/2015)... DUBLIN , Jan. 28, 2015 Research ... announced the addition of the "Global Biometrics ... Use, Regions and Countries " report to their ... market, Asia-Pacific is anticipated ... by 2015, owing to increasing government spending towards ...
(Date:1/22/2015)... 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry ... new website design. "When we launched FindBiometrics 12 ... Peter O,Neill , founder and CEO of FindBiometrics. "Now it,s ... from the key players on a very broad scale.  We ...
(Date:1/22/2015)... , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... commerce market, reports on the recent success of the Wocket™ smart wallet ... Wocket smart wallet was named as one of the "11 Hot ... "5 Best Products Launched At CES So Far" by Newseveryday.com and "The ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... new and environmentally friendly process for producing biodiesel fuel ... pounds of poultry industry waste that accumulate annually in ... the July 22 issue of ACS, Journal of ... In the study Mano Misra, Susanta Mohapatra, Narasimharao Kondamudi, ...
... Applying biological molecules from cell membranes to the ... the very basics of cell-to-cell interaction. Two ... biophysicist and colleagues suggest that putting lipids and ... lead to new classes of self-assembling materials for ...
... defective mitochondrial protein called MCLK1 produce elevated amounts of ... according to a study in this week,s JBC these ... longer than normal mice. Mitochondrial oxidative stress is ... reactive oxygen species produced by mitochondria while they make ...
Cached Biology News:New windows opened on cell-to-cell interactions 2New windows opened on cell-to-cell interactions 3
... the standard water based mounting medium for ... permanent preservation of peroxidase and alkaline phosphatase ... use and exhibits excellent optical characteristics. Crystal ... medium that permits the long-term storage of ...
... Custom monoclonal antibody development to targets ... small molecules, DNA, and cancer-specific surface antigens. ... phases and is completed in approximately 40 ... the nature of antigens). Phase I: ...
PCR System for increased fidelity, yield and length of PCR products. Amplifies targets up to 10 kb from human genomic DNA....
...
Biology Products: